Havila Kystruten AS: Havila Pollux back in operation
From tomorrow, November 7th, Havila Pollux will be back in operation and will resume her southbound route from Trondheim. Since October 31st, the ship has undergone warranty work at Fosen Shipyard and had one of her electric motors replaced.
Of passengers whose journeys with Havila Pollux were interrupted, some chose to transfer their trips to one of the company's other ships or opt for the upcoming round trip with Havila Pollux starting from Bergen on Wednesday, November 8th.
Despite the mentioned cancellations, there have been very few technical disruptions to Havila Kystruten’s operations in 2023, and the company can boast an operational stability rate of over 99%.
New measurements show an average CO2 emissions reduction of 37% so far this year, with a reduction in local emissions, NOx and SOx, by more than 90%. The company is very pleased with these results and has received full funding from the NOx Fund.
The company has had a positive development in the 3rd quarter, with all four ships finally in full operation. There has been positive feedback from travelers, a high demand for bookings in the 4th quarter of 2023, and the company has already achieved 50% of its booking target for 2024.
CEO Bent Martini, +47 905 99 650
CFO Arne Johan Dale, +47 909 87 706
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)27.2.2024 21:52:04 CET | Press release
Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955). The study, A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections is being conducted under a contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Approximately 80 sites
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons27.2.2024 21:42:24 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameAnthony Pagano2.Reason for the notificationa)Position/statusExecutive Vice President & Chief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction pla
Capital Increase in Genmab as a Result of Employee Warrant Exercise27.2.2024 21:40:01 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00, 19,631 shares at DKK 1,032.00, 2,473 shares at DKK 1,050.00, 1,422 shares at DKK 1,161.00, 40 shares at DKK 1,334.50, 1,036 shares at DKK 1,362.50, 6,660 shares at DKK 1,402.00, 129 shares at DKK 1,408.00, and 9,713 shares at DKK 1,615.00. Proceeds to the company are approximately DKK 58.7 million. The increase corresponds to approximately 0.07% of the company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as
Nova Klúbburinn hf. birtir uppgjör fjórða ársfjórðungs og ársins 202327.2.2024 18:43:15 CET | Press release
Sterkur vöxtur þjónustutekna skilar sér í hækkun EBITDA, auknum hagnaði og betra sjóðstreymi Helstu niðurstöður á fjórða ársfjórðungi: Heildartekjur voru 3.327 m.kr. á fjórða ársfjórðungi 2023 samanborið við 3.354 m.kr. á Á samanburðarári tekjufærði félagið einskiptislið að fjárhæð 39 m.kr. vegna sölu eigna, leiðrétt fyrir því er 0,05% tekjuvöxtur á milli áraÞjónustutekjur námu samtals 2.424 m.kr. og vaxa um 3,4% á milli ára EBITDA nam 961 m.kr. samanborið við 978 m.kr. á sama tímabili á fyrra ári, EBITDA hlutfallið var 28,9% á fjórðungnum samanborið við 29,2% á fyrra ári Hagnaður fjórða ársfjórðungs var 182 m.kr. og hækkar um 3,9%Handbært fé frá rekstri á fjórðungnum er 1.010 m.kr. samanborið við neikvætt 110 m.kr. á sama tímabili á fyrra ári Helstu niðurstöður ársins 2023: Heildartekjur voru 12.993 m.kr. á árinu 2023 samanborið við 12.641 m.kr. á árinu 2022 og vaxa um 2,8% milli áraÞjónustutekjur námu samtals 9.734 m.kr. og vaxa um 6,8% á milli ára EBITDA nam 3.979 m.kr. og hækkar um
Open Society Foundations’ Soros Economic Development Fund Commits $25 Million to Allied Climate Partners’ Climate Finance Partnership27.2.2024 18:41:57 CET | Press release
New York, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The Soros Economic Development Fund (SEDF), the impact investment arm of the Open Society Foundations, is committing $25 million to Allied Climate Partners (ACP)—a new and innovative public-private partnership focused on increasing the number of bankable climate projects in emerging markets and developing economies around the world. ACP aims to address a critical financing gap at the early, risk-oriented stages of the development process. Without this support, many projects and businesses struggle to attract the necessary capital to achieve their climate-related goals. While early-stage project development represents the smallest portion of the overall funding needed for a project (approximately 5 percent), relatively few early-stage projects get financed due to risk. Even though 5 percent of the capital can unlock 95 percent, this early-stage capital is the hardest to raise for critical activities like technical and environmental assessments